Sign in

    Corey Davis

    Managing Director and Senior Equity Analyst at Canaccord Genuity Group Inc.

    Corey Davis is a Managing Director and Senior Equity Analyst at Canaccord Genuity Group Inc., specializing in biotechnology and life sciences coverage. He is recognized for his in-depth research on companies such as Amgen, Regeneron, and other leading biotech firms, maintaining a solid track record with positive returns and high rankings on investment research platforms. Corey began his analyst career in the early 2000s, previously holding roles at LifeSci Advisors before joining Canaccord Genuity, and has established a reputation for insightful coverage and sector expertise. He holds FINRA Series 7, 63, and 86/87 licenses, reflecting strong professional credentials and regulatory compliance.

    Corey Davis's questions to ZFGN leadership

    Corey Davis's questions to ZFGN leadership • Q4 2015

    Question

    Corey Davis of Canaccord questioned the lack of a clear dose response in the trials, the potential outcomes of the FDA meeting, the projected 2016 cash burn, and whether second-generation compounds could be advanced while beloranib is on clinical hold.

    Answer

    CMO Dennis Kim explained the studies were not powered to show a dose difference. CEO Tom Hughes outlined various potential FDA outcomes, emphasizing the focus on the Prader-Willi syndrome (PWS) indication. CFO Patty Allen confirmed the cash guidance includes planned clinical expenses for both beloranib and the second-generation compound. Hughes added that early trials for the new compound could occur outside the U.S.

    Ask Fintool Equity Research AI